期刊文献+

高分辨率熔解曲线分析法检测结直肠癌KRAS基因突变 被引量:1

Detection of KRAS Mutations in Colorectal Cancer by High Resolu tion Melting Analysis
下载PDF
导出
摘要 目的:采用高分辨率熔解曲线分析法检测结直肠癌中KRAS基因突变,探讨其用于临床检测的可行性。方法:首先用高分辨率熔解曲线分析法检测64例结直肠癌患者KRAS基因第2外显子的突变情况,再用直接测序法对结果进行验证。结果:通过高分辨率熔解曲线分析法检测,发现有23例KRAS基因突变(35.9%),经直接测序法验证,证实所有患者的突变情况与高分辨率熔解曲线法的结果完全一致;共检测出6种KRAS突变类型,G12D(GGT>GAT)的突变率最高(47.8%),G12D、G12V和G13D等3种常见突变型占总突变数的78.3%。结论:与直接测序法相比,应用高分辨率熔解曲线分析法检测KRAS基因突变具有操作简单快捷、结果准确、成本低的优点,适合应用于临床检测。 Objective: To evaluate the feasibility of detecting the KRAS mutations in colorectal cancer patients by high resolution melting curve analysis.Methods: KRAS exon 2 mutations were performed on 64 patients with colorectal cancer by high resolution melting analysis and direct sequencing.Results: KRAS exon 2 mutations were detected in a total of 23 patients(35.9%) with the two methods combined,comprising 6 different mutant alleles.Three common mutations G12D,G12V and G13D accounted for 78.3% of all cases,mutations of G12D was the highest(47.8%).The concordant rate between the two methods was 100%.Conclusion: Compared with direct se quencing,high resolution melting curve analysis is accurate,convenient,efficient and economical,which is suitable for clinic test.
出处 《生物技术通讯》 CAS 2012年第5期701-703,共3页 Letters in Biotechnology
基金 传感技术联合国家重点实验室基金资助项目(skt1003) 广东省自然科学基金博士启动项目(10451001002004935)
关键词 结直肠癌 KRAS基因 突变 高分辨率熔解曲线 colorectal cancer KRAS gene mutation high resolution melting
  • 相关文献

参考文献9

  • 1van Cutsem E, Kohene C H, Hitre E, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal can- cer[J]. N Engl J Med, 2009,360:1408-1417.
  • 2Bokemeyer C, Bondarenko I, Hartmann J T, et al. KRAS sta- tus and efficacy of first-line treatment of patients with meta- static; colorectal cancer(mCRC) with FOI,FOX with or without cetuximab: the OPUS experience[J]. J Clin Oncol, 2008,26(5): 4000.
  • 3Erali M, Wittwer C T. High resolution melting analysis for gene scanning[J]. Methods, 2010,50(4):250-261.
  • 4Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2009[J]. CA Cancer J Clin, 2009,59(4):225-249.
  • 5Soulieres D, Greer W, Maglioeco A M, el al. KRAS mutation testing in the treatment of metastatic colorectal cancer with anti-EGFR therapies[J]. Curr Oncol, 2010,17(1):31-40.
  • 6Siddiqui A D, Piperdi B. KRAS mutation in colon cancer: a marker of resistance to EGFR-I therapy[J]. Ann Surg Oncol, 2010,17(4):1168-1176.
  • 7Ma E S, Wong C L, Law F B, et al. Detection of KRAS mu- tations in colorectal cancer by high-resolution melting analysis [J]. J Clin Pathot. 2009,62(10):886-891.
  • 8Vandersteen J G. Bayrak-Toydemir P, Palais R A, et al. Iden- tifying common genetic variants by high-resolution melting[J]. Clin Chem, 2007,53(7):1191-1198.
  • 9Vossen R H, Aten E, Roos A, et al. High-resolution melting analysis(HRMA): more than just sequence variant screening [J]. Hum Mutat, 2009,30(6):860-866.

同被引文献29

  • 1Siegel R, Ma J, Zou Z, et al. Cancer statistics, 2014[J]. CA Cancer J Clin, 2014,64( 1 ) :9-29.
  • 2Engstrom PF, Arnoletti JP, Benson AB, et al. NCCN Clinical Practice Guidelines in Oncology: colon cancer[ J]. J Natl Compr Canc Netw, 2009,7 (8) :778-831.
  • 3Allegra C J, Jessup JM, Somerfield MR, et al. American Society of Clinical Oncology provisional clinical opinion : testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy [ J ]. J Clin Oncol, 2009,27 (12) : 2091-2096.
  • 4Cancer Genome Atlas Network. Comprehensive molecular characterization of human colon and rectal cancer [ J]. Nature, 2012,487 (7407) :330-337.
  • 5Pylayeva-Gupta Y, Grabocka E, Bar-Sagi D. RAS oncogenes: weaving a tumorigenic web[J]. Nat Rev Cancer,2011,11 ( 11 ) : 761-774.
  • 6Malapelle U, Carlomagno C, de Laca C, et al. KRAS testing in metastatic colorectal carcinoma : challenges, controversies, breakthroughs and beyond[J]:/Clin Pathol, 2014,67( 1 ) :1-9.
  • 7French D, Smith A, Powers MP, et al. KRAS mutation detection in colorectal cancer by a commercially available gene chip array compares well with Sanger sequencing [ J ]. Clin Chim Acta, 2011,412(17-18) :1578-1581.
  • 8Richman SD, Chambers P, Seymour MT, et al. Intra-tumoral heterogeneity of KRAS and BRAF mutation status in patients with advanced colorectal cancer (aCRC) and cost-effectiveness of muhiple sample testing [ J ]. Anal Cell Pathol ( Amst ) , 2011,34 (1-2) :61-66.
  • 9Baskin Y, Dagdeviren YK, Calibasi G, et al. KRAS mutation profile differences between rectosigmoid localized adenocareinomas and colon adenocarcinomas [ J]. J Gastrointest Oncol, 2014,5 (4) :265-269.
  • 10Van Cutsem E, Ktihne CH, L6ng I, et al. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status [ J]. J Clin Oneol, 2011,29(15) :2011-2019.

引证文献1

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部